ReviewReviews in cardiovascular medicine2025
Progress in Prognostic Metabolic Biomarkers for Coronary Artery Disease Patients Post-Percutaneous Coronary Intervention.
Review in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Percutaneous coronary intervention (PCI) has made significant progress as one of the main treatments for coronary artery disease (CAD), but the risk of major adverse cardiovascular events (MACE) after PCI remains high. Therefore, early identification of high-risk CAD patients after PCI and improvement of risk factors are crucial for patient prognosis. Although various prognostic biomarkers related to CAD have been identified, most of them have not been widely applied in clinical practice. Recent studies have found that some simple and easily obtainable metabolic indicators have early predictive value for the prognosis of CAD patients after PCI, mainly including four categories: blood lipids and related metabolites, blood glucose and related metabolites, nutrition-related metabolites, and kidney-related metabolites. This review synthesizes the four aforementioned categories of indicators with the aim of integrating their unique characteristics to enable precise prognostication in patients after PCI, deepen mechanistic insights, and furnish evidence-based guidance for clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.